Prosecution Insights
Prosecution Insights
3 pending office actions • 0 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hummingbird Bioscience Pte. Ltd. is managing 3 pending office actions. These 3 actions are distributed among 3 distinct examiners, which means each examiner is responsible for one matter. This spread across 3 distinct examiners suggests that the company's prosecution results will be influenced by several different individual styles. BELYAVSKYI, MICHAIL A is the busiest examiner, holding 1 pending office action.
With 3 pending office actions and 3 distinct examiners, the company must navigate three separate review styles. This personnel diversity requires practitioners to tailor their responses to each individual's specific concerns. Monitoring the specific preferences and historical allowance rates of each of the 3 distinct examiners may provide strategic advantages during the response phase.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 1 | 64.2% | +27.6% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
| MERTZ, PREMA MARIA | 1 | 71.7% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18403476 | HER3-BINDING ANTIBODY-DRUG CONJUGATE | STONEBRAKER, ALYSSA RAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692314 | TREATMENT AND PREVENTION OF CANCER USING VISTA ANTIGEN-BINDING MOLECULES | BELYAVSKYI, MICHAIL A | — |
| 18403476 | HER3-BINDING ANTIBODY-DRUG CONJUGATE | STONEBRAKER, ALYSSA RAE | — |
| 18518192 | VISTA ANTIGEN-BINDING MOLECULES | MERTZ, PREMA MARIA | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692314 | TREATMENT AND PREVENTION OF CANCER USING VISTA ANTIGEN-BINDING MOLECULES | BELYAVSKYI, MICHAIL A | — | §102§103§112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18403476 | HER3-BINDING ANTIBODY-DRUG CONJUGATE | STONEBRAKER, ALYSSA RAE | — | §101§102§103§112 | Non-Final OA | — | Pending | Jan 03, 2024 |
| 18518192 | VISTA ANTIGEN-BINDING MOLECULES | MERTZ, PREMA MARIA | — | §102§112DP | Non-Final OA | — | Pending | Nov 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial